



ERKNet

The European
Rare Kidney Disease
Reference Network



Monogenic Hypertension

Rosa Vargas-Poussou
Paris, France




Hyperkalemia

hypokalemia

↑Na⁺ reabsorption → ↑Volemia → ↑Blood pressure

Familial Hyperkalemic Hypertension
Gordon syndrome
Type 2 Pseudo-hypoaldosteronism



Aldosterone

Renin

MR

Cortisol → Cortisone

Apparent mineralocorticoid excess (AME)

Liddle syndrome




Geller syndrome
(hypertension during pregnancy)

Gordon Syndrome

Familial Hyperkaliemic Hypertension


PseudoHypoaldosteronism type 2

- First description 1960
- Hypertension, normal renal function
- Autosomal dominant transmission
- Hyperkalaemia, hypochloraemia, metab. acidosis
- Low plasma renin, +/- low aldosterone
- High sensitivity to thiazide diuretics



Achard, *Clin Exp Pharmacol Physiol*. 2001, *Am J Med* 2003


Clinical Presentation



	Age (years)	Sex (M/F)	BMI (Kg/m ²)	BP (mmHg)	K ⁺ (mmol/L)	Creatinine (μmol/L)
Father	36	M	26.2	160/100	5.6-6.4	74
Grandmother	58	F	25.4	170/95	5.2-5.7	65
Daughter	10	F	17.8	120/80	5.3-5.5	42
Son	6	M	15.2	110/70	5.5-5.8	37

	CO ₂ T (mmol/L)	Cl- (mmol/L)	Renin act. (ngAl/ml/h)	Aldost. (pg/ml)	Response to HCTZ
Father	18-26	111	0.08	152	++
Grandmother	22	112	-	-	+
Daughter	17-21	111	0.5	144	++
Son	16-20	113	0.4	91	++



Gene ?
1q31-q42



WNK4
17q21.2


2001

WNK1
12p13.33



KLHL3
5q31.2

2012



CUL3
2q35

PHA IIA

PHA IIB



PHA IIC

PHA IID


PHA IIE

Wilson FH et al Science 2001

Boyden LM et al Nature 2012
Louis-Dit-Picard H et al. Nat Genet 2012












Up-regulation of the NCC
Increased Na⁺ reabsorption




Reduced K⁺ secretion by Kir 1.1 (ROMK) channel

Autosomal recessive and dominant








Hypercalciuria

Jiang Y et al.
AJP Renal Physiology 2007
Yang SS et al.
Endocrinology 2010
TRPV5/6 ??

Acidosis

López-Cayuqueo KI, et al.
A mouse model of PHAII reveals a novel mechanism of renal tubular acidosis.
Kidney Int. 2018




Gordon syndrome : Phenotype/Genotype

Patients	<i>CUL3</i>	<i>KLHL3</i>	<i>KLHL3</i>	<i>WNK4</i>	<i>WNK1</i>	<i>WNK1</i>
	HeteroZ Δex9	HomoZ	HeteroZ	HeteroZ (ex 7-17)	HeteroZ Δintron-1	HeteroZ acidic motif (ex7)
	n = 14	n = 4	n = 16	n = 6	n = 3	n = 26
Age (years)	6,6 [1,3-28]	8.4 [0,3-17]	35,9 [15-56]	31 [5-45]	39 [13-71]	23 [0,1-59]
SBP (mmHg)	160 [124-190]	153 [130-170]	148 [103-190]	147 [107-180]	146 [126-166]	117 [90-148]
DBP (mmHg)	98 [80-115]	90 [71-110]	92 [53-115]	88 [59-110]	89 [76-102]	75 [43-116]
K+ (mmol/L)	7,1 [5,8-9,6]	6.0 [5,1-7,3]	5,9 [5,3-6,7]	5,7 [5,5-6,4]	5,7 [5,3-6,1]	5,6 [5,0-7,1]
Cl- (mmol/L)	112 [104-120]	109 [71-110]	107 [103-112]	113 [109-119]	107 [104-110]	108 [102-112]

Marzukiewicz, in preparation

Severe arterial hypertension from Cullin-3 mutations is caused by both renal and vascular effects




doi:10.1681/ASN.2017121307

Waed Abdel Khalek et al. JASN 2019;30:811-823

JASN
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

JASN


Gene ?
1q31-q42




2001

WNK1
12p13.33

WNK4
17q21.2



KLHL3
5q31.2



2012


CUL3
2q35



	PHA IIA	PHA IIB	PHA IIC	PHA IID	PHA IIE
Affected	36% (?)	5%	4%	40%	15%
Inheritance	AD	AD	AD	AD, AR	AD
Type of mutations	?	Intron 1 del. Missense Ex 7	Missense Ex 7 and 17	Missense Others	Splice Ex 9



Apparent mineralocorticoid excess (AME) Ulick syndrome

- Autosomal recessive transmission
- Severe Hypertension (insidious end-organ damage)
- Low plasma renin and aldosterone
- Hypokalaemia
- Low birth weight and failure to thrive
- Polyuria and polydipsia
- Nephrocalcinosis
- Urinary elevated ratio of cortisol (F) to cortisone (E) metabolites
- Cases with mild phenotype (AME type 2)




Apparent mineralocorticoid excess (AME)


Mutations in the *HSD11B2* gene




Genotype–phenotype correlations in apparent mineralocorticoid excess (AME).



	L114, Δ 6nt	R186C	-	L250P.L251S	R337C	E356, Δ 1nt	R374X	D185V+F367del	F185S	R213C	A328V	Q342fs
Low birth weight	+	+	-	+	-	+	+	-	+	+	-	-
Hypokalemia	++	+	-	++	(+)	++	++	(+)	-	++	+	++
Hypertension	++	++	+	++	++	++	++	++	++	++	++	++
(THF+5 α THF)/THE	40	13	3	40	9	60	50	4	2.5	13	22	26







Clinical profile for patients with AME due to HSD11B2 deficiency from seven nations of the International Consortium for Rare Steroid Disorders.



Mabel Yau et al. PNAS 2017;114:52:E11248-E11256


PNAS

Clinical profile for patients with AME due to HSD11B2 deficiency from seven nations of the International Consortium for Rare Steroid Disorders.




Median age at diagnosis 4.6 y (0.1–15)
86% were born at term
76% were small for GA
75% presented nephrocalcinosis

G



Disruptive mutations affecting the dimer interface of HSD11B2.

A



B

Mutant	Disease		Engineered		
	$\Delta\Delta G$ (kcal/mol)	Mutant	$\Delta\Delta G$ (kcal/mol)	Mutant	$\Delta\Delta G$ (kcal/mol)
G89D	0.5	P227L	0.3	D91N	1.6
D144V	1.7	Y232C	3.8	E115G	3.3
D176N	2.1	A237V	0.8	E115K	2.6
L179R	0.5	D244N	1.1	Y232F	1.0
S180F	1.2	L250R	2.3	K236R	0.3
F185S	1.5	L250P	3.2	R335K	2.2
R186C	4.2	L251S	0.4	R335Q	1.6
R208H	1.7	T267A	0.4	R335A	2.6
R208C	4.8	R279C	4.1	R336K	1.2
R213C	4.8	A328V	0.7	R336A	1.3
A221V	0.4	R337C	2.8	R336Q	2.4
A221G	1.3	Y338H	2.9	R337K	4.1
D223N	1.0	R359W	4.0	R337A	2.8
Y226N	2.0			R337Q	3.0

Not studied: L363P, L376P

Severe AME:
mutants that enhance dimerization
Disrupt the substrate- or coenzyme-binding site,
or severely impair structural stability.

Mild AME (type 2): P227L, R279C, and R359W
indirectly disrupting substrate binding or causing
mild alterations in protein structure.

PNAS

Mabel Yau et al. PNAS 2017;114:52:E11248-E11256

Apparent mineralocorticoid excess (AME)



Follow-up data – n = 16

- Cardiovascular complications
 - 3 patients died from cardiac arrest at 16, 16, and 17 yr.
 - Left ventricular hypertrophy :12/16
 - Hypertensive retinopathy: 10/16
 - For the 13 surviving patients:
 - 12 had persistent left ventricular hypertrophy,
 - 3 showed aortic root dilation,
 - 2 had aortic insufficiency.
 - Other complications
 - Nephrocalcinosis: present in 8/9 patients after 4.1–14.5 y.
 - CKD: 4 patients developed 10 y after diagnosis.
 - Renal transplantation: 2 patients. Remission of the low-renin hypertension and hypokalemic

Liddle Syndrome







First description in 1963

- Autosomal dominant transmission
- Severe or moderate Hypertension
- Hypokalaemia
- Metabolic alkalosis
- Low plasma renin and aldosterone





	Mother	Children				
		II-1	III-1	III-2	III-3	III-4
Age	43	23	21	19	15	
Sex	F	M	F	M	M	
BMI (kg/m ²)	20.4	19.6	23.3	23.2	18.1	
Age at diagnosis	28	21	-	19	14	
BP (no treatment)	192/96	174/125	124/72	180/111	155/112	
BP (amiloride)	134/83	138/74	-	127/80	129/81	

Liddle Syndrome – Data at diagnosis




Liddle Syndrome


Gain-of-function subunits of ENaC



ENaC




Ubiquitination



Liddle syndrome

PY motif

a	--ALTAPPAYATLGP _{PP} RP--
b	--IPGT _{PPP} NYDSLRLQP--
g	--VPGT _{PPP} KYNTLRLER--




Cell surface accumulation

A Missense Mutation in the Extracellular Domain of Alpha ENaC Causes Liddle Syndrome

METHODS

Phenotypic, genetic, and electrophysiological characterization of a novel Liddle family (resistant hypokalemic hypertension) without mutations in β - or γ -ENaC



OUTCOME The C479R mutation increased amiloride-sensitive ENaC current in oocytes ~2-fold due to higher open probability



CONCLUSION

Novel mutation in extracellular domain α ENaC causes Liddle syndrome by increasing channel activity

Mahdi Salih, Ivan Gautschi, Miguel X. van Bemmelen, Michael Di Benedetto, Alice S. Brooks, Dorien Lugtenberg, Laurent Schild, Ewout J. Hoorn. A Missense Mutation in the Extracellular Domain of Alpha ENaC Causes Liddle Syndrome. *JASN*. ASN.2016111163
doi:10.1681/JASN.2016111163





JASN
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

JASN

Mahdi Salih et al. *JASN* 2017;28:3291-3299

Hypertension Exacerbated by Pregnancy Geller Syndrome

- Autosomal dominant transmission
- Low-renin and low-aldosterone hypertension
- Hypokalaemia
- Early onset
- Worsening during pregnancy





Activating Mineralocorticoid Receptor Mutation

Clinical parameter	MR _{L810} ⁺ (=8)	MR _{L810} ⁻ (n=11)	P
Age	29.1 ± 6.3	32.9 ± 8.1	0.88
HTN < age 20	100 %	0 %	<0.0001
anti-HTN medication	1.5 ± 0.27	0.2 ± 0.12	0.0001
SBP (mmHg)	167 ± 11	126 ± 10	0.014
DBP (mmHg)	110 ± 6	78 ± 6	0.002
Serum K ⁺ (mM)	3.91 ± 0.18	4.36 ± 0.11	0.08
Serum HCO ₃ ⁻ (mM)	27.1 ± 0.87	26.4 ± 0.83	0.59
Serum aldosterone (ng/dl)	2.48 ± 0.68	12.1 ± 2.96	0.008
Urinary aldosterone (μg/24 hrs)	<2	7.75 ± 1.55	0.03

Hypertension Exacerbated by Pregnancy

Gain of function mutation of mineralocorticoid receptor



Treatment



	Gordon syndrome	Apparent mineralocorticoid excess	Liddle syndrome	Hypertension exacerbated by pregnancy
Main treatment	Thiazides diuretics	<u>MR Antagonists:</u> spironolactone or eplerenone <u>Dexamethasone</u>	<u>ENaC Blockers</u> Amiloride Triamterene	Amiloride
Other treatments	Amlodipine (for CUL3 patients)	Amiloride		

Conclusion - Monogenic hypertension

- ✓ Diseases associated with increase of Na reabsorption in the DCT and CD
- ✓ Low renin hypertension
- ✓ Abnormal plasma potassium
- ✓ Precise diagnosis is important for:
 - ✓ Genetic counselling
 - ✓ Specific and early treatment
 - ✓ Prevention of complications



ERKNet

The European
Rare Kidney Disease
Reference Network

Next webinar: June 25, "XLH
Recommendations"

Dieter Haffner
Hannover (Germany)